Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer Dr. Stemmer, the study principal investigator currently treating liver cancer patients under compassion

from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer

TIKVA, Israel, January 07, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline

of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the principal investigator

of the Company's Phase II liver cancer study, Dr. Solomon Stemmer, will deliver a presentation titled "The Safety

and Efficacy of Namodenoson in the Second-Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh

B (CPB) Liver Cirrhosis: A Phase 2 , Randomized, Double-Blind, Placebo-Controlled Trial" at the Israeli Society of Clinical

Oncology and Radiotherapy (ISCORT) annual conference on January 8, 2020 11:00 am.

completed Phase II liver cancer study found that Namodenoson increased overall survival in HCC patients with Child Pugh B7 (CPB7),

the largest subpopulation of the study, as compared to placebo, even though the trial did not meet its primary endpoint. The Company

recently completed a successful End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA), in which the FDA agreed

with Can-Fite's proposed pivotal Phase III trial design to support a New Drug Application (NDA) submission and approval

of Namodenoson in the treatment of HCC.

ISCORT is the most prestigious Israel oncology forum to discuss novel treatments in different malignancies and enable the creation

of collaboration between leading investigators in the field. We are confident that Dr. Stemmer's presentation will open

the door for the participation of leading oncologists in the Company's Phase III study", said Dr. Fishman, Can Fite

is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson

is being evaluated as a second line treatment for hepatocellular carcinoma, with a recently completed Phase II trial and planned

Phase III trial in this indication. The drug is currently in an ongoing Phase II trial as a treatment for non-alcoholic fatty

liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression

is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.

Can-Fite BioPharma Ltd.

BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology

that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.

The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's

liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of

liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted

Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food

and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate,

and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical

studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These

drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information

please visit: www.can-fite.com.

press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among

other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations,

strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking

statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe,"

"expect," "intend," "plan," "may," "should" or "anticipate"

or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate

strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various

filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the

approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected

events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that

have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual

results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could

cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking

statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking

statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and

our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working

capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate

development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical

studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory

filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability

to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model

and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for

intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual

property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political

and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite's filings with the

SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are

highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation

to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.